Cheviot Value Management LLC lowered its stake in Becton, Dickinson and Company (NYSE:BDX) by 0.5% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 20,508 shares of the medical instruments supplier’s stock after selling 107 shares during the period. Becton, Dickinson and accounts for 2.1% of Cheviot Value Management LLC’s holdings, making the stock its 18th largest position. Cheviot Value Management LLC’s holdings in Becton, Dickinson and were worth $3,762,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. Cantillon Capital Management LLC raised its stake in shares of Becton, Dickinson and by 30.3% in the first quarter. Cantillon Capital Management LLC now owns 1,344,427 shares of the medical instruments supplier’s stock valued at $246,622,000 after buying an additional 312,926 shares during the last quarter. JPMorgan Chase & Co. increased its position in Becton, Dickinson and by 6.5% in the first quarter. JPMorgan Chase & Co. now owns 3,967,843 shares of the medical instruments supplier’s stock valued at $727,863,000 after buying an additional 242,081 shares during the period. Prudential Financial Inc. increased its position in Becton, Dickinson and by 34.0% in the first quarter. Prudential Financial Inc. now owns 930,445 shares of the medical instruments supplier’s stock valued at $170,681,000 after buying an additional 236,280 shares during the period. Montag & Caldwell LLC purchased a new position in Becton, Dickinson and during the first quarter valued at $34,713,000. Finally, Private Advisor Group LLC increased its position in Becton, Dickinson and by 2,402.0% in the first quarter. Private Advisor Group LLC now owns 184,972 shares of the medical instruments supplier’s stock valued at $10,190,000 after buying an additional 177,579 shares during the period. 75.57% of the stock is currently owned by institutional investors.

Becton, Dickinson and Company (BDX) traded down 0.81% during midday trading on Friday, hitting $197.69. The company had a trading volume of 989,225 shares. Becton, Dickinson and Company has a 12-month low of $161.29 and a 12-month high of $206.63. The company’s 50 day moving average is $199.72 and its 200 day moving average is $188.69. The stock has a market cap of $44.99 billion, a price-to-earnings ratio of 57.25 and a beta of 1.05.

Becton, Dickinson and (NYSE:BDX) last posted its earnings results on Thursday, August 3rd. The medical instruments supplier reported $2.46 earnings per share for the quarter, beating the Zacks’ consensus estimate of $2.44 by $0.02. The business had revenue of $3.04 billion for the quarter, compared to analysts’ expectations of $3.06 billion. Becton, Dickinson and had a net margin of 6.25% and a return on equity of 22.53%. The firm’s revenue for the quarter was down 5.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.35 earnings per share. On average, equities analysts anticipate that Becton, Dickinson and Company will post $9.46 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, September 29th. Investors of record on Friday, September 8th will be paid a $0.73 dividend. The ex-dividend date is Thursday, September 7th. This represents a $2.92 dividend on an annualized basis and a yield of 1.48%. Becton, Dickinson and’s payout ratio is currently 83.43%.

TRADEMARK VIOLATION WARNING: This report was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this report on another site, it was copied illegally and republished in violation of United States & international copyright and trademark law. The original version of this report can be viewed at https://www.thecerbatgem.com/2017/08/19/cheviot-value-management-llc-sells-107-shares-of-becton-dickinson-and-company-bdx-updated-updated-updated.html.

A number of equities research analysts have commented on the company. Barclays PLC restated an “equal weight” rating and issued a $210.00 target price (up previously from $205.00) on shares of Becton, Dickinson and in a research report on Thursday, August 10th. BidaskClub cut Becton, Dickinson and from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st. Zacks Investment Research cut Becton, Dickinson and from a “buy” rating to a “hold” rating in a research note on Thursday, May 4th. Stifel Nicolaus reaffirmed a “buy” rating on shares of Becton, Dickinson and in a research note on Wednesday, August 9th. Finally, Evercore ISI raised Becton, Dickinson and from an “in-line” rating to an “outperform” rating and boosted their target price for the stock from $186.00 to $200.00 in a research note on Monday, April 24th. One research analyst has rated the stock with a sell rating, five have issued a hold rating, nine have given a buy rating and one has issued a strong buy rating to the stock. Becton, Dickinson and currently has a consensus rating of “Buy” and an average target price of $195.79.

In other Becton, Dickinson and news, insider Nabil Shabshab sold 6,149 shares of the company’s stock in a transaction dated Tuesday, August 15th. The shares were sold at an average price of $201.76, for a total transaction of $1,240,622.24. Following the sale, the insider now directly owns 15,648 shares of the company’s stock, valued at $3,157,140.48. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, VP Jeffrey S. Sherman sold 28,765 shares of the company’s stock in a transaction dated Thursday, May 25th. The stock was sold at an average price of $185.98, for a total transaction of $5,349,714.70. Following the sale, the vice president now directly owns 70,821 shares in the company, valued at $13,171,289.58. The disclosure for this sale can be found here. In the last three months, insiders sold 57,631 shares of company stock worth $11,112,178. 1.40% of the stock is currently owned by insiders.

About Becton, Dickinson and

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Stock Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related stocks with our FREE daily email newsletter.